Press releases

GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+

GSK today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for FLULAVAL® QUADRIVALENT (Influenza Vaccine). This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses, in persons three years of age and older.

Read more - GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+ Read more

Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance

Leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, call on governments and industry to work in parallel in taking comprehensive action against drug-resistant infections

Read more - Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance Read more

FDA approves expanded use of GSK Hib vaccine from booster dose to full series

GSK [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration approved an expanded age indication for HIBERIX® [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)]. HIBERIX® is now indicated for the immunization of children aged six weeks through four years (prior to 5th birthday) against invasive disease caused by Haemophilus influenzae type b (Hib). Hib infection is a serious disease caused by bacteria usually affecting children under the age of five, and Hib vaccination for appropriate children is routinely recommended.

Read more - FDA approves expanded use of GSK Hib vaccine from booster dose to full series Read more

ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with Janssen Sciences Ireland UC (Janssen) for the phase III investigation and commercialisation of the long-acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) for the treatment of HIV-1 infection.

Read more - ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection Read more